FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 27, 2026
Monopar Therapeutics Inc. (MNPR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $13.7 million. As of Jun 30, 2026 it held $105.4 million in cash and investments and $205,663 in total debt.
Revenue
$0
Net income (TTM)
$-17.84M
-3.1% vs year-ago TTM
Operating cash flow (TTM)
$-12.18M
-24.1% vs year-ago TTM
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
6.69M
+9.5% vs prior year
Net cash
$105.16M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmette, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1645469
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M |
| Operating cash flow | -$12.2M | -$6.4M | -$7.9M | -$7.2M | -$7.3M |
| Total assets | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M |
| Total liabilities | $2.9M | $5.3M | $1.8M | $3.1M | $1.6M |
| Stockholders' equity | $137.8M | $55.0M | $5.6M | $10.1M | $18.9M |
| Cash and investments | $122.7M | $91.3M | $13.8M | $13.1M | $20.3M |
| Total debt | $245,489 | — | $8,408 | $56,990 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
All 536 Monopar Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.